Steven Masson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven Masson has a total of 399 co-authors. Here are the top co-authors by number of shared publications:
- Stuart McPherson
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
8 shared publications - Richard Parker
Leeds Liver Unit St James's University Hospital Leeds UK
5 shared publications Aileen Marshall
Royal Free Hospital, London, UK
4 shared publicationsDouglas Thorburn
Royal Free Hospital, London, United Kingdom
4 shared publications- Ewan Forrest
Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK
4 shared publications - Guruprasad Padur Aithal
Department of Hepatology Nottingham University Hospitals NHS Trust Nottingham UK
4 shared publications
Latest Publications
- 24 August 2026
- Published by BMJ in Frontline Gastroenterology
The UK Clinical Guidelines for Alcohol Treatment (2025): an overview for gastroenterologists
In November 2025, the Department of Health and Social Care of the UK Government published the Clinical Guidelines for Alcohol Treatment with the aim to improve outcomes for people experiencing harmful alcohol use and alcohol dependence by supporting service planners, commissioners and providers to deliver high-quality care. The guidelines are comprehensive; however, their size means that identifying areas of particular relevance to gastroenterologists and hepatologists can be difficult. This article aims to highlight those aspects of the guidelines which may be of interest to those working in gastroenterology. This review highlights sections of the guideline related to physical health risks of alcohol, detection and assessment of liver disease, assessment of alcohol use disorder in acute hospitals, the management of alcohol withdrawal and Wernicke’s encephalopathy, the general treatment of alcohol-related liver disease, relapse prevention and driving advice. This review highlights the priorities for gastroenterologists described in these national guidelines.
- 24 August 2026
- Published by BMJ in Frontline Gastroenterology
The UK Clinical Guidelines for Alcohol Treatment (2025): an overview for gastroenterologists
In November 2025, the Department of Health and Social Care of the UK Government published the Clinical Guidelines for Alcohol Treatment with the aim to improve outcomes for people experiencing harmful alcohol use and alcohol dependence by supporting service planners, commissioners and providers to deliver high-quality care. The guidelines are comprehensive; however, their size means that identifying areas of particular relevance to gastroenterologists and hepatologists can be difficult. This article aims to highlight those aspects of the guidelines which may be of interest to those working in gastroenterology. This review highlights sections of the guideline related to physical health risks of alcohol, detection and assessment of liver disease, assessment of alcohol use disorder in acute hospitals, the management of alcohol withdrawal and Wernicke’s encephalopathy, the general treatment of alcohol-related liver disease, relapse prevention and driving advice. This review highlights the priorities for gastroenterologists described in these national guidelines.
- Open Access
- 20 July 2026
- Published by Elsevier in American Journal of Transplantation
Waitlist suspension is associated with persistent reduction in access to liver transplantation
- 20 July 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessWaitlist suspension is associated with persistent reduction in access to liver transplantation
- Open Access
- 16 November 2025
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 61 (1)
Characteristics of alcohol care teams in England: results of the ProACTIVE National Survey
Aims: This study aimed to identify (i) the number of alcohol care teams (ACTs) in England, (ii) the characteristics of patients supported by ACTs, and (iii) the service structure and care components offered by ACTs. Methods: All acute hospitals (i.e. those providing short-term high-dependency medical care) in England were approached to complete a survey of alcohol care provision. Surveys were completed through researcher-guided interviews by staff familiar with the hospital’s alcohol provision. It featured questions on service structure, patient characteristics, service functions, and policies. Data collection took place between May and October 2023. Results: Of 170 hospitals approached, 122 completed a survey and 80 reported having an ACT. Most ACT patients were male (mean 64.1%; 95% confidence interval (CI) 61.8–66.4), white (mean 79.2%; 95% CI 75.1–83.4), aged 45–54 (mean 27.8%; 95% CI 25.0–30.5), and experiencing severe alcohol dependence (mean 66.2%; 95% CI 36.8–95.7). Most services had a clinical lead but only 58% funded this role. Fifty-nine percent of services operated 7 days per week. Most services reported identification and brief advice, though it was rarely systematized. Nearly all supported medically assisted alcohol withdrawal, though a quarter of patients did not complete medically assisted alcohol withdrawal before discharge. Conclusions: ACT numbers increased significantly between 2019 and 2024. They offer a clinical service to highly vulnerable and complex patients. There is significant variation in ACT operational models, training, and leadership which will impact the effectiveness of identification strategies and management of patients with comorbid alcohol use disorder within acute medical settings.
- 16 November 2025
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 61 (1)
Open AccessCharacteristics of alcohol care teams in England: results of the ProACTIVE National Survey
Aims: This study aimed to identify (i) the number of alcohol care teams (ACTs) in England, (ii) the characteristics of patients supported by ACTs, and (iii) the service structure and care components offered by ACTs. Methods: All acute hospitals (i.e. those providing short-term high-dependency medical care) in England were approached to complete a survey of alcohol care provision. Surveys were completed through researcher-guided interviews by staff familiar with the hospital’s alcohol provision. It featured questions on service structure, patient characteristics, service functions, and policies. Data collection took place between May and October 2023. Results: Of 170 hospitals approached, 122 completed a survey and 80 reported having an ACT. Most ACT patients were male (mean 64.1%; 95% confidence interval (CI) 61.8–66.4), white (mean 79.2%; 95% CI 75.1–83.4), aged 45–54 (mean 27.8%; 95% CI 25.0–30.5), and experiencing severe alcohol dependence (mean 66.2%; 95% CI 36.8–95.7). Most services had a clinical lead but only 58% funded this role. Fifty-nine percent of services operated 7 days per week. Most services reported identification and brief advice, though it was rarely systematized. Nearly all supported medically assisted alcohol withdrawal, though a quarter of patients did not complete medically assisted alcohol withdrawal before discharge. Conclusions: ACT numbers increased significantly between 2019 and 2024. They offer a clinical service to highly vulnerable and complex patients. There is significant variation in ACT operational models, training, and leadership which will impact the effectiveness of identification strategies and management of patients with comorbid alcohol use disorder within acute medical settings.
- 17 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1364-1371
Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease
INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.
- 17 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (6) , 1364-1371
Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease
INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.
- Open Access
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Diabetes mellitus in alcohol-associated liver disease: Prevalence and outcomes
Background: Alcohol associated liver disease (ALD) is a common condition that is a significant global cause of morbidity and mortality. Diabetes mellitus (DM) increases the risk of adverse outcomes in other types of steatotic liver disease. This retrospective study sought to explore the relationship between ALD and DM. Methods: The Worldwide Alcohol-related Liver Disease Outcomes (WALDO) study is an international multicenter cohort of patients with biopsy-proven ALD. The presence of DM at baseline or during follow-up was noted. Clinical events after index biopsy were noted, including death and liver-associated clinical events (LACE). Risks for adverse outcomes were assessed with Cox proportional hazard models with DM as a time-dependent variable to reflect periods of time without or with diabetes. All analyses were done in R. Results: In total, 712 patients with a median age of 52 years were followed up for a median of 4.8 years (IQR: 1.2–9.5). At baseline, DM was present in 113 patients (15.9%), and a further 56 patients (7.8%) developed DM in follow-up. During follow-up, 113 patients developed LACE. One hundred fifty-two patients died from liver disease, and 46 underwent liver transplantation. DM was significantly associated with liver-related mortality (HR: 1.77, 1.15–2.73, p=0.009) and incident LACE (HR: 1.90, 1.23–2.95, p=0.004). In multivariable analysis, DM remained significantly associated with liver-related mortality (HR=1.79, 1.30–2.48, p<0.001). Conclusions: DM is a frequent comorbidity in persons with ALD and is associated with a higher risk of liver-related mortality. Patients’ diabetic status should be an important consideration for clinicians treating people with ALD.
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Open AccessDiabetes mellitus in alcohol-associated liver disease: Prevalence and outcomes
Background: Alcohol associated liver disease (ALD) is a common condition that is a significant global cause of morbidity and mortality. Diabetes mellitus (DM) increases the risk of adverse outcomes in other types of steatotic liver disease. This retrospective study sought to explore the relationship between ALD and DM. Methods: The Worldwide Alcohol-related Liver Disease Outcomes (WALDO) study is an international multicenter cohort of patients with biopsy-proven ALD. The presence of DM at baseline or during follow-up was noted. Clinical events after index biopsy were noted, including death and liver-associated clinical events (LACE). Risks for adverse outcomes were assessed with Cox proportional hazard models with DM as a time-dependent variable to reflect periods of time without or with diabetes. All analyses were done in R. Results: In total, 712 patients with a median age of 52 years were followed up for a median of 4.8 years (IQR: 1.2–9.5). At baseline, DM was present in 113 patients (15.9%), and a further 56 patients (7.8%) developed DM in follow-up. During follow-up, 113 patients developed LACE. One hundred fifty-two patients died from liver disease, and 46 underwent liver transplantation. DM was significantly associated with liver-related mortality (HR: 1.77, 1.15–2.73, p=0.009) and incident LACE (HR: 1.90, 1.23–2.95, p=0.004). In multivariable analysis, DM remained significantly associated with liver-related mortality (HR=1.79, 1.30–2.48, p<0.001). Conclusions: DM is a frequent comorbidity in persons with ALD and is associated with a higher risk of liver-related mortality. Patients’ diabetic status should be an important consideration for clinicians treating people with ALD.
- Open Access
- 1 April 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
The clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation: the LIFT prospective RCT
Background: Long-term surviving liver transplant recipients can spontaneously develop operational tolerance, which allows them to completely discontinue their immunosuppression, but we lack validated tools to predict the likelihood of rejection following immunosuppression withdrawal. A previous clinical trial showed that a logistic regression algorithm including the transcript levels of a set of five genes in a liver biopsy could predict the success of immunosuppression withdrawal with high sensitivity and specificity. Objective: To determine if the use of a liver tissue transcriptional test of tolerance to stratify liver recipients prior to immunosuppression withdrawal accurately identifies operationally tolerant recipients and reduces the incidence of rejection, as compared with a control group in whom immunosuppression withdrawal is performed without stratification. Design and methods: Prospective, multicentric, phase IV, biomarker-strategy design trial with a randomised control group in which adult liver transplant recipients were randomised 1 : 1 to either: (1) non-biomarker-based immunosuppression weaning (Arm A); or (2) biomarker-based immunosuppression weaning (Arm B). Setting and participants: Adult liver transplant recipients ≥ 3 years post transplant (≥ 6 years if age ≤ 50 years old) with no history of autoimmunity or recent episodes of rejection, normal allograft function, and no significant histological abnormalities in a baseline screening liver biopsy, recruited from 12 transplant units in United Kingdom, Germany, Belgium and Spain. Intervention: Enrolled patients underwent a screening liver biopsy to exclude the presence of subclinical allograft damage. Eligible participants randomised to Arm A underwent gradual discontinuation of immunosuppression. Among participants allocated to Arm B, only those found to be biomarker-positive were offered immunosuppression withdrawal, while biomarker-negative participants remained on their baseline immunosuppression. Patients who completely discontinued immunosuppression and maintained stable allograft function underwent protocol liver biopsies at 12 and 24 months after immunosuppression withdrawal. Main outcome measure: Development of operational tolerance, defined as the successful discontinuation of immunosuppression with maintenance of normal allograft status 12 and 24 months after immunosuppression withdrawal. Results: One hundred and twenty-two patients were eligible to participate in the trial, 116 were randomised (58 to Arm A and 58 to Arm B), 80 initiated immunosuppression withdrawal and 34 were maintaining on their baseline immunosuppression. Among the 80 patients who initiated withdrawal, 54 (67.5%) developed clinically apparent rejection, 22 (27.5%) successfully discontinued immunosuppression, 21 underwent a liver biopsy and 13 (16.3%) met the histological criteria of operational tolerance at 12 months after immunosuppression discontinuation. The transcriptional tolerance biomarker was not accurate at identifying patients meeting the operational tolerance criteria [odds ratio 1.466, 95% confidence interval (CI) 0.326 to 9.215; p = 0.744; Sensitivity (Sn) 54%, Specificity (Sp) 42%, positive predictive value 16%, and negative predictive value 81%, with an accuracy of 44%]. Due to the poor diagnostic performance of the test, the trial was terminated prematurely following an interim analysis of the results. No patients lost their grafts as a result of rejection during the study duration. Conclusions: In selected liver transplant recipients, immunosuppression withdrawal proved to be feasible, but was successful in a much lower proportion of patients than originally estimated. A previously validated liver tissue transcriptional biomarker test was not considered accurate in predicting the success of immunosuppression withdrawal. Study registration: Current Controlled Trials ISRCTN47808000 and EudraCT 2014-004557-14. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 13/94/55) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 3. See the NIHR Funding and Awards website for further award information.
- 1 April 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Open AccessThe clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation: the LIFT prospective RCT
Background: Long-term surviving liver transplant recipients can spontaneously develop operational tolerance, which allows them to completely discontinue their immunosuppression, but we lack validated tools to predict the likelihood of rejection following immunosuppression withdrawal. A previous clinical trial showed that a logistic regression algorithm including the transcript levels of a set of five genes in a liver biopsy could predict the success of immunosuppression withdrawal with high sensitivity and specificity. Objective: To determine if the use of a liver tissue transcriptional test of tolerance to stratify liver recipients prior to immunosuppression withdrawal accurately identifies operationally tolerant recipients and reduces the incidence of rejection, as compared with a control group in whom immunosuppression withdrawal is performed without stratification. Design and methods: Prospective, multicentric, phase IV, biomarker-strategy design trial with a randomised control group in which adult liver transplant recipients were randomised 1 : 1 to either: (1) non-biomarker-based immunosuppression weaning (Arm A); or (2) biomarker-based immunosuppression weaning (Arm B). Setting and participants: Adult liver transplant recipients ≥ 3 years post transplant (≥ 6 years if age ≤ 50 years old) with no history of autoimmunity or recent episodes of rejection, normal allograft function, and no significant histological abnormalities in a baseline screening liver biopsy, recruited from 12 transplant units in United Kingdom, Germany, Belgium and Spain. Intervention: Enrolled patients underwent a screening liver biopsy to exclude the presence of subclinical allograft damage. Eligible participants randomised to Arm A underwent gradual discontinuation of immunosuppression. Among participants allocated to Arm B, only those found to be biomarker-positive were offered immunosuppression withdrawal, while biomarker-negative participants remained on their baseline immunosuppression. Patients who completely discontinued immunosuppression and maintained stable allograft function underwent protocol liver biopsies at 12 and 24 months after immunosuppression withdrawal. Main outcome measure: Development of operational tolerance, defined as the successful discontinuation of immunosuppression with maintenance of normal allograft status 12 and 24 months after immunosuppression withdrawal. Results: One hundred and twenty-two patients were eligible to participate in the trial, 116 were randomised (58 to Arm A and 58 to Arm B), 80 initiated immunosuppression withdrawal and 34 were maintaining on their baseline immunosuppression. Among the 80 patients who initiated withdrawal, 54 (67.5%) developed clinically apparent rejection, 22 (27.5%) successfully discontinued immunosuppression, 21 underwent a liver biopsy and 13 (16.3%) met the histological criteria of operational tolerance at 12 months after immunosuppression discontinuation. The transcriptional tolerance biomarker was not accurate at identifying patients meeting the operational tolerance criteria [odds ratio 1.466, 95% confidence interval (CI) 0.326 to 9.215; p = 0.744; Sensitivity (Sn) 54%, Specificity (Sp) 42%, positive predictive value 16%, and negative predictive value 81%, with an accuracy of 44%]. Due to the poor diagnostic performance of the test, the trial was terminated prematurely following an interim analysis of the results. No patients lost their grafts as a result of rejection during the study duration. Conclusions: In selected liver transplant recipients, immunosuppression withdrawal proved to be feasible, but was successful in a much lower proportion of patients than originally estimated. A previously validated liver tissue transcriptional biomarker test was not considered accurate in predicting the success of immunosuppression withdrawal. Study registration: Current Controlled Trials ISRCTN47808000 and EudraCT 2014-004557-14. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 13/94/55) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 3. See the NIHR Funding and Awards website for further award information.
- Open Access
- 18 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1045-1058
Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression
- 18 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1045-1058
Open AccessRandomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression
- Open Access
- 13 October 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 46, 101067
Liver transplantation for critically ill patients with acute on chronic liver failure: a prospective national programme of waitlist prioritisation
- 13 October 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 46, 101067
Open AccessLiver transplantation for critically ill patients with acute on chronic liver failure: a prospective national programme of waitlist prioritisation
- 1 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , 615-621
Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort
- 1 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , 615-621
Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort
- 10 September 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (7) , 976-977
Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
LINKED CONTENT: This article is linked to McPherson et al papers. To view these articles, visit https://doi.org/10.1111/apt.18061 and https://doi.org/10.1111/apt.18171.
- 10 September 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (7) , 976-977
Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
LINKED CONTENT: This article is linked to McPherson et al papers. To view these articles, visit https://doi.org/10.1111/apt.18061 and https://doi.org/10.1111/apt.18171.